Medicines Marketed by Glenmark Pharmaceuticals Ltd

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a prominent Indian multinational pharmaceutical company that has been operating in the pharmaceutical sector since its establishment in 1977. Founded by Gracias Saldanha, the company is headquartered in Mumbai, Maharashtra, India, and has a significant global presence with 14 manufacturing facilities located in India, Argentina, the US, and the Czech Republic.

Glenmark Pharmaceuticals Ltd serves a global consumer base, with employees based out of over 50 offices worldwide. The company's mission is to enrich lives globally by improving the quality of life of patients across the globe through its research, development, and manufacturing of pharmaceutical products, including branded, generic, and over-the-counter (OTC) formulations.

Glenmark Pharmaceuticals Ltd Products

Glenmark Pharmaceuticals Ltd develops and manufactures a wide range of pharmaceutical products across various therapeutic areas, including respiratory therapy, dermatology, oncology, diabetes, cardiovascular, oral contraceptives, and more. The company stands out in the market due to its strong focus on innovation and research, with four R&D centres continuously developing new medicines and biosimilars.

Some of the notable products from Glenmark Pharmaceuticals Ltd include Ryaltris, a fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR); FabiFlu, a potential COVID-19 treatment medicine launched in India; and Envafolimab, a licensed product for oncology indications in several regions. The company's extensive product portfolio and presence in multiple therapeutic areas, along with its global partnerships and regulatory approvals from the US FDA and other international bodies, demonstrate its adherence to international standards and quality, making it a versatile and reliable player in the pharmaceutical industry.